Evidence map›Paper›PMID 27526323›Full record

ArticleNature genetics2016

Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.

Haiyang Guo, Musaddeque Ahmed, Fan Zhang, Cindy Q Yao, SiDe Li, Yi Liang, Junjie Hua, Fraser Soares, Yifei Sun, Jens Langstein and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 4 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 4 syntheses or guidelines pooled it, 230 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Perspectives of long non-coding RNAs in cancer.Molecular biology reports · 2017
    Pooled it
  4. Pooled it
  5. The Role ofMedicina (Kaunas, Lithuania) · 2020
    Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Computational and structural biotechnology journal · 2024
    Review
  18. Article
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 9 institutions in 4 countries.

Haiyang GuoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Musaddeque AhmedPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Fan ZhangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Cindy Q YaoOntario Institute for Cancer Research, Toronto, Ontario, Canada.
SiDe LiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yi LiangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Junjie HuaPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Fraser SoaresPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Yifei SunDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jens LangsteinPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Yuchen LiPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Christine PoonPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Swneke D BaileyPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Kinjal DesaiDepartment of Genetics, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA.
Teng FeiDepartment of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Qiyuan LiMedical College of Xiamen University, Xiamen, China.
Dorota H SendorekOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Michael FraserPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
John R PrensnerMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Trevor J PughPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-8073-5888
Mark PomerantzDepartment of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Robert G BristowPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Mathieu LupienPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0003-0929-9478
Felix Y FengDepartment of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA.
Paul C BoutrosOntario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0003-0553-7520
Matthew L FreedmanDepartment of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Martin J WalshDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Housheng Hansen HePrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0003-2898-3363
University Health Network · CAIcahn School of Medicine at Mount Sinai · USOntario Institute for Cancer Research · CADana-Farber Cancer Institute · USBroad Institute · USDartmouth College · USUniversity of California, San Francisco · USUniversity of Michigan · USXiamen University · CN

Funding

Defining the epigenetic landscape in human prostate cancerR01CA193910 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A, FREEDMAN, MATTHEW L · 2015 to 2019
$3.1M
Chromatin Dynamics of the CFTR locusR01HL103967 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WALSH, MARTIN JOHN · 2011 to 2014
$1.9M
CIHR 142246NCI NIH HHS R01 CA193910NHLBI NIH HHS R01 HL103967
6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) represent an attractive class of candidates to mediate cancer risk. Through integrative analysis of the lncRNA transcriptome with genomic data and SNP data from prostate cancer genome-wide association studies (GWAS), we identified 45 candidate lncRNAs associated with risk to prostate cancer. We further evaluated the mechanism underlying the top hit, PCAT1, and found that a risk-associated variant at rs7463708 increases binding of ONECUT2, a novel androgen receptor (AR)-interacting transcription factor, at a distal enhancer that loops to the PCAT1 promoter, resulting in upregulation of PCAT1 upon prolonged androgen treatment. In addition, PCAT1 interacts with AR and LSD1 and is required for their recruitment to the enhancers of GNMT and DHCR24, two androgen late-response genes implicated in prostate cancer development and progression. PCAT1 promotes prostate cancer cell proliferation and tumor growth in vitro and in vivo. These findings suggest that modulating lncRNA expression is an important mechanism for risk-associated SNPs in promoting prostate transformation.

Indexed as

Gene Expression Regulation, NeoplasticGenetic Predisposition to DiseasePolymorphism, Single NucleotideRNA, Long NoncodingAnimalsCell Line, TumorChromatinEnhancer Elements, GeneticGenome-Wide Association StudyGenotypeHumansMaleMiceMice, Inbred NODProstatic NeoplasmsReceptors, AndrogenChromatinPCAT-1 lncRNA, humanReceptors, AndrogenRNA, Long NoncodingTranscription Factors

Identifiers

PMID27526323
OpenAlexW2511381148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.